AB40. Sexual Side Effects of Medical Treatment of BPH

    September 2014 in “ PubMed Central
    Hyun Jun Park
    TLDR BPH treatments can cause sexual side effects affecting quality of life.
    The document discussed the sexual side effects associated with the medical treatment of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). It highlighted that five alpha reductase inhibitors, such as finasteride and dutasteride, were effective for BPH but could lead to sexual side effects like loss of libido, erectile dysfunction, and decreased ejaculatory volume. Additionally, alpha adrenergic blockers, despite their efficacy and low adverse effects, could cause retrograde and diminished ejaculation. The document emphasized that while the prevalence of these side effects was not high, their impact on patients' quality of life was significant and should be considered alongside the treatments' efficacy for BPH/LUTS.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 137 results

      community EU Shouldn't Ban Fin & Dut: PFS is NOT REAL.

      in Research/Science  11 upvotes 11 months ago
      Finasteride and Dutasteride do not cause depression or "Post Finasteride Syndrome," with concerns often linked to the nocebo effect and preexisting mental health issues. The EU is unlikely to ban these drugs, but access may become more restricted due to ongoing debates.

      community Massive study on finasteride side effects released

      in Finasteride/Dutasteride  83 upvotes 2 years ago
      The release of a study on 5a-reductase inhibitors (finasteride and dutasteride) which showed an increased risk of depression, dementia, decreased libido, and reduced semen load as potential side effects; discussion around other forms of hair loss treatments such as topical minoxidil, RU58841, or opting to accept baldness; and advice to consider professional help for deeper issues related to hair loss.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 1 year ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

    Related Research

    3 / 3 results